SARA DAVIS: Open Payments
NPI 1720137995 · ASHEBORO, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,897 in 98 payments from 22 companies in 2025. Trend: 2023 $2,033 · 2024 $2,017 · 2025 $1,897
Food & beverage: $1,897
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $418 |
| AstraZeneca Pharmaceuticals LP | 11 | $317 |
| Novo Nordisk Inc | 13 | $210 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $123 |
| Xeris Pharmaceuticals, Inc. | 4 | $104 |
| Amgen Inc. | 6 | $92 |
| GlaxoSmithKline, LLC. | 3 | $91 |
| Phathom Pharmaceuticals, Inc. | 4 | $67 |
| Lilly USA, LLC | 3 | $60 |
| Dynavax Technologies Corporation | 3 | $54 |
Products named: VRAYLAR, AIRSUPRA, Ozempic, CAPLYTA, BREZTRI, QULIPTA, TRELEGY ELLIPTA, VOQUEZNA.
Industry payments across NC — which companies pay providers there.
